Detailed answers about KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD, including incorporation, status, business activity, and accounts information.
When was KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD founded?
KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD was officially incorporated on 9 June 2023 and is registered under company number SC772173. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD?
KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD do?
KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD operates in the following sector: 72110 - Research and experimental development on biotechnology. This provides insight into the company's primary business activity and industry focus.
What is KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD's registered address?
The registered office address of KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD is 3/2 10 SOUTHCROFT STREET, GLASGOW, SCOTLAND, G51 2BJ. This is the official address filed with Companies House for legal and statutory correspondence.
Is KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD financially stable?
The most recent accounts for KACHEZ CLINICAL RESEARCH TECHNOLOGY SUPPLY LTD were made up to 30 June 2025, filed as DORMANT. Next accounts are due by 31 March 2027.